Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Recurrent Acute Pancreatitis
NCT06253117Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute pancreatitis (AP) comparing Placebo with Pirfenidone (2 arms). Primary endpoint: Adverse Events at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT06253117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253117.